Clinical trial
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma…
NCT00087451 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00087451 |
|---|---|
| Title | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) |
| Official title | A Phase I Sequential Ascending Dose Trial of AP23573 in Patients With Progressive or Recurrent Malignant Glioma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Glioma, Glioblastoma, Gliosarcoma |
| Intervention type | Drug |
| Interventions | AP23573 |
| Enrollment | 11 |
| Start date | Jul 1, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Jul 13, 2004 |
| Last update posted | Aug 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: